RIPK1 targeting protects against obesity and atherosclerosis
Authors:
- 1 July 2021
- journal article
- editorial
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 32 (7) , 420-422
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Impact of myeloid RIPK1 gene deletion on atherogenesis in ApoE-deficient miceAtherosclerosis, 2021
- OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1 during murine liver inflammationCell Death & Differentiation, 2021
- RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in MiceCirculation, 2021
- RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophagesCell Death & Differentiation, 2020
- RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in miceNature Metabolism, 2020
- OxLDL-mediated immunologic memory in endothelial cellsJournal of Molecular and Cellular Cardiology, 2020
- Fructose stimulated de novo lipogenesis is promoted by inflammationNature Metabolism, 2020
- LXR Activation Induces a Proinflammatory Trained Innate Immunity-Phenotype in Human MonocytesFrontiers in Immunology, 2020
- Altered Cellular Metabolism Drives Trained ImmunityTrends in Endocrinology & Metabolism, 2018
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010